|Bid||87.68 x 800|
|Ask||0.00 x 1200|
|Day's Range||87.02 - 87.96|
|52 Week Range||61.05 - 89.93|
|Beta (3Y Monthly)||1.05|
|PE Ratio (TTM)||29.36|
|Earnings Date||Oct 24, 2019|
|Forward Dividend & Yield||0.88 (1.01%)|
|1y Target Est||92.43|
Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on...
Baxter International Inc. (BAX), a leading global medical products company, today announced that it has been named to Working Mother magazine’s 2019 ‘Best Companies for Dads’ list for the first time. Baxter is focused on creating a positive and supportive work environment for all working parents and continues to expand on paternity and gender-neutral parental leave and flexible schedules. "We’re honored to be named one of the ‘Best Companies for Dads’ and recognized as an inclusive company for working parents and caregivers,” said José (Joe) E. Almeida, chairman and chief executive officer.
The regulatory go-ahead for Abbott's (ABT) ARCHITECT STAT High Sensitivity Troponin-I blood test is a major stride forward in its commitment for detecting patients suspected of having a heart attack.
Baxter new #HomeDialysis study associates Sharesource with 39% reduction in hospitalization rates for Colombian patients. #PeritonealDialysis #KidneyDisease: https://bit.ly/2nZEh0O
Baxter International Inc. (BAX), a leading global medical products company, will showcase its latest product innovations at the 2019 European Society of Intensive Care Medicine (ESICM) LIVES congress in Berlin from Sept. 28 – Oct. 2. The company will also host symposia to advance clinical knowledge in two emerging areas: extracorporeal (outside the body) organ support and the role of personalized fluid management for patients in the intensive care unit (ICU).
Baxter International Inc. , a global leader in clinical nutrition, is also present at the ESMO congress to be held in Barcelona from 27 September to 1 October, organizin
Strong international footprint, solid prospects in the global orthopedic space and an enhanced product pipeline bode well for Wright Medical (WMGI). However, adverse forex mars prospects.
Illumina (ILMN) pins high hopes on almost a dozen new drugs unveiled with a predictive biomarker (nine of which are already approved for oncology indications).
Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.
PRA Health (PRAH) expects to enhance position and capabilities in the data and analytics field with the new tool, while simplifying treatment decisions.
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, contraction in gross margin remains a woe.